Current Opinion in Cardiology was launched in 1985. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of cardiology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Dr Sherif Nagueh has a longstanding interest in the evaluation of cardiac function, particularly left ventricular diastolic function. He was the chair of the writing group for the ASE/EAE guidelines on the echocardiographic evaluation of left ventricular diastolic function. He has done extensive research in the diagnosis and management of patients with myocardial diseases, especially dilated and hypertrophic cardiomyopathy and he was the chair of the multimodality imaging guidelines for patients with hypertrophic cardiomyopathy. Dr Nagueh serves as Director of the Echocardiography Laboratory at the Houston Methodist DeBakey Heart & Vascular Center, USA.
He has several clinical studies looking at left ventricular diastolic function in patients with and without heart failure and hypertrophic cardiomyopathy.
In addition to his clinical and research work, Dr Nagueh is a devoted educator, and has won numerous teaching awards. He has taught principles and clinical applications of echocardiography to cardiology fellows and sonographers for two decades. His lectures cover topics such as the use of doppler for calculation of flow and pressure gradients, assessment of left ventricular diastolic function, and echocardiographic assessment of patients with hypertrophic cardiomyopathy. As part of his commitment to education, Dr Nagueh serves as a board member, editor, and peer reviewer for many cardiology publications. He has published extensively in leading cardiology journals and has also contributed numerous textbook chapters.
Dr Andrew Pipe graduated from Queen's University, Canada, in 1974. Formerly Chief of the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute, Canada, Dr Pipe continues his research and clinical work in this setting. Dr Pipe is a Professor in the Faculty of Medicine at the University of Ottawa and Chair-elect of the Heart and Stroke Foundation of Canada.
He is currently involved in clinical research assessing new approaches to smoking cessation, strategies designed to facilitate exercise adoption, and novel initiatives to prevent cardiovascular disease.
Dr Pipe has addressed audiences in over 30 nations and is frequently consulted on issues related to tobacco use and smoking cessation, drug use in sport, and physical activity and health.
In addition to his clinical responsibilities, Dr Pipe has been extensively involved in sports and sport medicine for many years. He served as a physician at 12 Olympic Games. A member of the Canadian Olympic Hall of Fame (Builder), he served as Chair of the Canadian Centre for Ethics in Sport from its inception until 2003 and is a Past-President of the Canadian Academy of Sport and Exercise Medicine.
Dr Pipe is the recipient of the International Olympic Committee's Award for “Sport, Health and Wellbeing” and honourary degrees from Queen's University (LLD), Brock University (DSc) and University of Guelph (DSc), in Canada. He was the former Vice Chairman of the Board of Trustees at Queen's University. In 2002, he was named to the Order of Canada.
Dr Bobby Yanagawa is a surgeon in the Division of Cardiac Surgery at St Michael's Hospital, Canada. He is an Assistant Professor, Division of Cardiac Surgery at the University of Toronto, Canada. Dr Yanagawa obtained his BSc and PhD from the University of British Columbia, Canada, and his MD degree and Cardiac Surgery Residency from the University of Toronto.
He has completed research fellowships at the University of Wales College of Medicine, Cardiff, UK, National Cardiovascular Center, Osaka, Japan, and at St Michael's Hospital. He completed a clinical fellowship at Mount Sinai Hospital, New York.
His clinical and research interests are in arterial revascularization and valvular surgery. Dr Yanagawa currently maintains a translational science laboratory focused on the pathogenesis of valvular heart disease. He has published over 55 peer reviewed papers, 29 reviews and 15 book chapters. He has published in Nature Communications, Nature Medicine, Circulation, Journal of Thoracic and Cardiovascular Surgery and Annals of Thoracic Surgery. He was the AATS 13th Annual C. Walton Lillehei Award winner in 2010.
Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto, Canada. He is the Canada Research Chair in Cardiovascular Surgery and former recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is a member of the American Association of Thoracic Surgeons (AATS) and the College of New Scholars, Artists and Scientists, Royal Society of Canada. Dr Verma has an h-index of 65, with 16,483 total citations to 331 publications.
Dr Verma has co-authored two state-of-the-art NEJM reviews on mitral valve repair and bicuspid aortopathy. His surgical-centric meta-analysis has been used by the American College of Cardiology, USA, and the Canadian Cardiovascular Society (CCS) to shape the recommendations for best revascularization choice in individuals with diabetes. He is a past/present contributor to several CCS guidelines, an author of the 2018 Diabetes Canada guidelines and is involved in the latest AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.
Dr Verma's clinical trial work focus on diabetes, dyslipidemia and heart failure. He is a steering committee member of the international EMPEROR-Reduced and EMPEROR-Preserve trials and national lead investigator of the global Dapa-HF trial. He also spearheads the CARDIOLINK clinical trials platform at St. Michael's Hospital.
Dr Verma also oversees a pre-clinical research team that focuses on identifying novel biomarkers in cardiovascular health and developing innovative cardiovascular remedies. This research program has yielded 2 United States patents and is supported by the Canadian Foundation for Innovation, Canadian Institutes of Health Research (CIHR) and Heart & Stroke Foundation (HSF).